Competitor Analysis - Cardiometabolic Peptides, New Report Launched

The Competitive Intelligence Report Cardiometabolic Peptides as of November 2014 provides a competitor analysis in the development pipeline of peptide therapeutics for treatment of diabetes, obesity and atherosclerosis. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides a compilation of currently active projects in research and development for novel cardiometabolic peptides.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication
• R&D Stage

Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 77 pages, “Competitor Analysis: Cardiometabolic Peptides” report covering the 2013 Sales of Major CardioMetabolic Peptides, Selective Peptide GLP-1 Receptor Agonists for CardioMetabolic Diseases, Dual Target Peptide GLP-1 Agonists for CardioMetabolic Diseases, Other Peptides for Diabetes, Other Peptides for Obesity & Lipodystrophy, Other Peptides for Diabetes and Obesity & Cardiometabolic Disease, Peptides for Atherosclerosis, Corporate Cardiometabolic Peptide R&D Pipelines

Know more about this report at – http://mrr.cm/ZC4

Find all Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare